Meng, Da
Carvajal, Richard D.
Funding for this research was provided by:
Vagelos College of Physicians and Surgeons, Columbia University
Article History
First Online: 1 February 2019
Compliance with Ethical Standards
:
: Da Meng was funded by the Columbia University Vagelos College of Physicians and Surgeons 2018 Summer Research Program for the preparation of this manuscript.
: Richard D. Carvajal is a consultant for AstraZeneca, Bristol-Myers Squibb, Castle Biosciences, Foundation Medicine, Immunocore, Incyte Merck, Novartis, Roche/Genentech, Aura Biosciences, Chimeron, and Rgenix. Da Meng has no conflicts of interest that might be relevant to the contents of this manuscript.